📊 NERV Key Takeaways
Is Minerva Neurosciences, Inc. (NERV) a Good Investment?
Minerva Neurosciences exhibits severe financial distress with negative stockholders' equity of -$254M, zero revenue, and annual net losses of $125.4M. The company is burning $5.4M in operating cash annually against a $32.7M cash reserve, creating an estimated 6-year runway at current burn rates unless it achieves immediate commercialization or secures dilutive financing.
Minerva is pre-revenue and posted an extreme net loss driven largely by non-operating items, leaving a substantial stockholders’ equity deficit despite manageable operating losses. While cash and liquidity are strong relative to current burn, the outsized liabilities and lack of revenue visibility create elevated balance sheet and execution risk.
Minerva Neurosciences, Inc. Key Strengths (NERV)
- Current cash position of $32.7M provides near-term operational runway of approximately 6 years at current burn rate
- Manageable long-term debt of only $4.8M minimizes debt service burden
- Strong current ratio of 17.65x indicates adequate short-term liquidity to meet immediate obligations
- Very strong liquidity and cash position
- Low long-term debt burden
- Operating cash burn manageable relative to cash
NERV Stock Risks: Minerva Neurosciences, Inc. Investment Risks
- Negative stockholders' equity of -$254M represents technical balance sheet insolvency with liabilities exceeding assets
- Zero commercial revenue generation with no demonstrated path to product commercialization
- Sustained negative operating cash flow of -$5.4M annually with shrinking cash runway and no profitability in sight
- Accumulated net losses of -$125.4M indicate inability to control operating expenses relative to revenue generation
- Likely requirement for dilutive equity financing, debt restructuring, or strategic alternatives to ensure survival
- Significant stockholders’ equity deficit and liabilities > assets
- No revenue; continued operating losses likely without approvals/partnerships
- Large non-operating charges suggest potential contingent obligations or future outflows
Key Metrics to Watch
- Revenue recognition from drug product commercialization or partnership milestones
- Monthly operating cash burn rate and revised liquidity runway analysis
- Stockholders' equity trajectory and timeline to positive equity restoration
- Clinical trial progress and regulatory approval status for pipeline candidates
- Financing announcements, dilution impact, and shareholder equity preservation
- Operating cash flow (burn rate)
- Stockholders’ equity (deficit) trend
Minerva Neurosciences, Inc. (NERV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.65x current ratio provides a solid financial cushion.
NERV Profit Margin, ROE & Profitability Analysis
NERV vs Healthcare Sector: How Minerva Neurosciences, Inc. Compares
How Minerva Neurosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Minerva Neurosciences, Inc. Stock Overvalued? NERV Valuation Analysis 2026
Based on fundamental analysis, Minerva Neurosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Minerva Neurosciences, Inc. Balance Sheet: NERV Debt, Cash & Liquidity
NERV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Minerva Neurosciences, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $0.19 reflects profitable operations.
NERV Revenue Growth, EPS Growth & YoY Performance
NERV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$8.1M | $-0.19 |
| Q2 2021 | N/A | -$8.8M | $-0.25 |
| Q1 2021 | N/A | -$8.8M | N/A |
| Q3 2020 | N/A | -$8.1M | $-0.19 |
| Q2 2020 | N/A | -$12.2M | $-0.32 |
| Q1 2020 | N/A | -$12.2M | N/A |
| Q3 2019 | N/A | -$12.0M | N/A |
| Q2 2019 | N/A | -$12.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Minerva Neurosciences, Inc. Dividends, Buybacks & Capital Allocation
NERV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Minerva Neurosciences, Inc. (CIK: 0001598646)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NERV
What is the AI rating for NERV?
Minerva Neurosciences, Inc. (NERV) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NERV's key strengths?
Claude: Current cash position of $32.7M provides near-term operational runway of approximately 6 years at current burn rate. Manageable long-term debt of only $4.8M minimizes debt service burden. ChatGPT: Very strong liquidity and cash position. Low long-term debt burden.
What are the risks of investing in NERV?
Claude: Negative stockholders' equity of -$254M represents technical balance sheet insolvency with liabilities exceeding assets. Zero commercial revenue generation with no demonstrated path to product commercialization. ChatGPT: Significant stockholders’ equity deficit and liabilities > assets. No revenue; continued operating losses likely without approvals/partnerships.
What is NERV's revenue and growth?
Minerva Neurosciences, Inc. reported revenue of $0.0.
Does NERV pay dividends?
Minerva Neurosciences, Inc. does not currently pay dividends.
Where can I find NERV SEC filings?
Official SEC filings for Minerva Neurosciences, Inc. (CIK: 0001598646) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NERV's EPS?
Minerva Neurosciences, Inc. has a diluted EPS of $-2.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NERV's fundamental grade?
Based on our AI fundamental analysis in May 2026, Minerva Neurosciences, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NERV stock overvalued or undervalued?
Valuation metrics for NERV: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NERV's AI grade for 2026?
Our dual AI analysis gives Minerva Neurosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NERV's free cash flow?
Minerva Neurosciences, Inc.'s operating cash flow is $-5.4M, with capital expenditures of $16.3K.
How does NERV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 17.65 (avg: 2).